These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 8895738

  • 1. The role of DNA mismatch repair in platinum drug resistance.
    Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD, Howell SB.
    Cancer Res; 1996 Nov 01; 56(21):4881-6. PubMed ID: 8895738
    [Abstract] [Full Text] [Related]

  • 2. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, Howell SB.
    Clin Cancer Res; 1997 Oct 01; 3(10):1763-7. PubMed ID: 9815561
    [Abstract] [Full Text] [Related]

  • 3. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M, Chauffert B.
    Cancer Chemother Pharmacol; 2002 Jun 01; 49(6):445-52. PubMed ID: 12107548
    [Abstract] [Full Text] [Related]

  • 4. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG.
    Cancer Res; 1998 Aug 15; 58(16):3579-85. PubMed ID: 9721864
    [Abstract] [Full Text] [Related]

  • 5. Loss of DNA mismatch repair in acquired resistance to cisplatin.
    Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB.
    Cancer Res; 1996 Jul 01; 56(13):3087-90. PubMed ID: 8674066
    [Abstract] [Full Text] [Related]

  • 6. Specificity of platinum-DNA adduct repair.
    Chaney SG, Vaisman A.
    J Inorg Biochem; 1999 Oct 01; 77(1-2):71-81. PubMed ID: 10626357
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Detection of an involvement of the human mismatch repair genes hMLH1 and hMSH2 in nucleotide excision repair is dependent on UVC fluence to cells.
    Lee DF, Drouin R, Pitsikas P, Rainbow AJ.
    Cancer Res; 2004 Jun 01; 64(11):3865-70. PubMed ID: 15172995
    [Abstract] [Full Text] [Related]

  • 16. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
    Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R.
    Cancer Res; 2000 Nov 01; 60(21):6039-44. PubMed ID: 11085525
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
    Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehmé A, Christen RD, Haas M, MacLeod CL, Howell SB.
    Cancer Res; 1997 May 15; 57(10):1841-5. PubMed ID: 9157971
    [Abstract] [Full Text] [Related]

  • 18. Differential involvement of the human mismatch repair proteins, hMLH1 and hMSH2, in transcription-coupled repair.
    Leadon SA, Avrutskaya AV.
    Cancer Res; 1997 Sep 01; 57(17):3784-91. PubMed ID: 9288788
    [Abstract] [Full Text] [Related]

  • 19. Human cells bearing homozygous mutations in the DNA mismatch repair genes hMLH1 or hMSH2 are fully proficient in transcription-coupled nucleotide excision repair.
    Rochette PJ, Bastien N, McKay BC, Therrien JP, Drobetsky EA, Drouin R.
    Oncogene; 2002 Aug 22; 21(37):5743-52. PubMed ID: 12173044
    [Abstract] [Full Text] [Related]

  • 20. Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner.
    Fedier A, Erdmann R, Boulikas T, Fink D.
    Int J Oncol; 2006 Nov 22; 29(5):1303-10. PubMed ID: 17016665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.